Krufton

Nilotinib Hydrochloride Dihydrate, the active ingredient in Krufton, is a tyrosine kinase inhibitor presented as a tablet for oral use. It selectively inhibits BCR‑ABL kinase activity to treat chronic myeloid leukemia in adult patients.

GNH USA supplies Krufton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Krufton is a targeted therapy that acts on the BCR‑ABL tyrosine‑kinase pathway in chronic myeloid leukemia. - Chronic phase CML: improves hematologic and cytogenetic response in Philadelphia chromosome‑positive patients. - Accelerated phase CML: helps achieve remission when disease progresses. - Imatinib‑resistant CML: provides an alternative oral option for patients who have failed prior tyrosine‑kinase inhibitor therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Rash: skin erythema or pruritus. - Fatigue: decreased energy levels. - Diarrhea: loose stools, often transient.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Pancreatitis: abdominal pain with elevated enzymes. - Severe liver injury: marked transaminase elevation or hepatitis. - Neutropenia: significant reduction in white blood cells. - Stevens‑Johnson syndrome: severe skin and mucosal reaction.

Patients should be monitored for cardiac, hepatic, and hematologic safety. - Cardiac monitoring: obtain baseline ECG and repeat periodically to assess QT interval. - Hepatic function: check liver enzymes before initiation and during therapy. - Electrolyte balance: correct hypokalemia and hypomagnesemia to reduce QT risk. - Drug interactions: avoid strong CYP3A4 inhibitors and concomitant QT‑prolonging agents. - Pregnancy and lactation: contraindicated unless benefits outweigh potential risks. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Nilotinib may interact with several concomitant medicines. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase nilotinib exposure. - QT‑prolonging drugs (e.g., amiodarone, sotalol): additive risk of arrhythmia. - Antacids containing aluminum or magnesium: reduce nilotinib absorption. Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin): may modestly raise levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib concentrations. - Warfarin: monitor INR as nilotinib can affect anticoagulant control.